
Opinion|Videos|November 27, 2024
Navigating Healthcare Access and Decision-Making
Key Takeaways
- Integrating HER2-directed therapies into NSCLC treatment requires alignment with existing protocols and timely updates to decision-making processes.
- Establishing frameworks for rapid incorporation of emerging therapies and fostering adaptive decision-making processes are essential strategies.
An analysis of challenges and strategies for integrating HER2-directed therapies into decision-making for NSCLC, with a focus on timely updates, collaborative efforts among stakeholders, and balancing equitable access with cost management.
Advertisement
Episodes in this series

Video content above is prompted by the following:
- What are the key challenges in integrating HER2-directed therapies into existing internal decision-making processes for NSCLC?
- What strategies can be employed to ensure timely updates to internal decision-making processes as new HER2-directed therapies emerge?
- How can collaboration between payers, providers, and manufacturers be leveraged to ensure equitable access to HER2-directed therapies while managing costs?
Newsletter
Stay ahead of policy, cost, and value—subscribe to AJMC for expert insights at the intersection of clinical care and health economics.
Advertisement
Latest CME
Advertisement
Advertisement
Trending on AJMC
1
Network Disconnection, Not Lesion Volume, Drives MS Cognition
2
Enfortumab Vedotin Plus Pembro Cuts Risk of Disease Progression, Death 60% for Patients With MIBC Who Can’t Have Chemo With Bladder Removal
3
Abemaciclib Plus Endocrine Therapy Improves Overall Survival in High-Risk Early Breast Cancer
4
Colorblind Devices, Longer-Wavelength Lasers Offer Safer Options for Darker Skin Tones: Ariella Kauvar, MD
5